These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 29744867

  • 1. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2018 Oct 15; 143(8):2029-2038. PubMed ID: 29744867
    [Abstract] [Full Text] [Related]

  • 2. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Eur J Pharm Biopharm; 2019 Mar 15; 136():120-130. PubMed ID: 30660696
    [Abstract] [Full Text] [Related]

  • 3. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2018 Nov 15; 137():47-55. PubMed ID: 30253203
    [Abstract] [Full Text] [Related]

  • 4. ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib.
    Li W, Sparidans RW, Martins MLF, El-Lari M, Lebre MC, van Tellingen O, Beijnen JH, Schinkel AH.
    Mol Cancer Ther; 2021 Jun 15; 20(6):1173-1182. PubMed ID: 33785654
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
    Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2020 Mar 15; 146(6):1631-1642. PubMed ID: 31304590
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).
    Li W, Sparidans R, El-Lari M, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Int J Pharm; 2020 Jan 05; 573():118842. PubMed ID: 31759109
    [Abstract] [Full Text] [Related]

  • 9. ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.
    Loos NHC, Retmana IA, Li W, Martins MLF, Lebre MC, Sparidans RW, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2022 Apr 05; 178():106137. PubMed ID: 35192958
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
    Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2015 Dec 05; 102():200-7. PubMed ID: 26361725
    [Abstract] [Full Text] [Related]

  • 17. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
    van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2019 Aug 05; 146():104297. PubMed ID: 31175939
    [Abstract] [Full Text] [Related]

  • 18. ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability.
    Li W, Lehutová D, Sparidans RW, Heydari P, Wang J, Lebre MC, Beijnen JH, Schinkel AH.
    Eur J Pharm Biopharm; 2022 Aug 05; 177():135-146. PubMed ID: 35772614
    [Abstract] [Full Text] [Related]

  • 19. P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
    Tang SC, Kort A, Cheung KL, Rosing H, Fukami T, Durmus S, Wagenaar E, Hendrikx JJ, Nakajima M, van Vlijmen BJ, Beijnen JH, Schinkel AH.
    Mol Pharm; 2015 Oct 05; 12(10):3714-23. PubMed ID: 26317243
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.